đź©şLeaN On Program: reducing the risk of lymphoedema
LeaN On - a research initiative led by Professor Bogda Koczwara and developed by Flinders University in partnership with BCNA, was developed in response to a long‑standing gap in survivorship care. Lymphoedema is a chronic condition affecting the arm or hand that can develop weeks, months or even years after breast cancer treatment, yet many people report receiving little guidance about early warning signs, risk reduction or when to seek support. LeaN On is an evidence‑based digital platform designed to support people who are living with, or concerned about, lymphoedema after breast cancer. The platform guides users through a simple 12‑step online journey, with each step offering small, manageable and practical information to help people: understand what lymphoedema is recognise early signs and symptoms take actions now to reduce risk know when and how to seek professional support The platform is currently being trialed through a research study, evaluating how lymphoedema support can be delivered online, including both self‑directed and nurse‑supported options. Its online design allows people to access guidance regardless of where they live, including in regional and rural areas where access to specialist care can be limited. Consumer perspectives have been embedded throughout the project. Participants for co‑design activities were recruited through the Review and Survey Group, and BCNA supported the research by appointing a trained Consumer Representative to the project team. This ensured lived experience informed both the development of the platform and the research approach. Both the platform and the study underpinning its development have now been published, and people affected by breast cancer are invited to trial LeaN On by contacting info@mylean.online Learn more about the LeaN On project: BCNA overview article Flinders University article and trial information Published study
Breast Cancer Prevention Research
Women who have undergone chemotherapy and radiotherapy for Hodgkin's Lymphoma (particularly those treated at a younger age) have an increased risk of going on to develop breast cancer. What is BCNA doing to advocate for research into the prevention of breast cancer in this patient cohort? For example, is research being conducted in Australia on the use of Tamoxifen to prevent the occurrence of breast cancer (BEFORE they are ever diagnosed with breast cancer) in this cohort?
